CBBT

Bloomberg Introduces New Fixed Income Pre-Trade TCA Model

Retrieved on: 
Wednesday, September 22, 2021
PGGM, News, Probability, Solution, Bloomberg Terminal, Multimedia, Bloomberg, CBBT, Technology, Intelligence, Research, Organization, Industry, TCA, Cryptocurrency, Security (finance)

The model has been calibrated based on five years of historical trade information, proprietary to Bloomberg taking a variety of factors into account.

Key Points: 
  • The model has been calibrated based on five years of historical trade information, proprietary to Bloomberg taking a variety of factors into account.
  • PGGM, a Bloomberg Transaction Cost Analysis (BTCA) solution customer, partnered with Bloomberg's trading quant research team to beta test Bloomberg's new pre-trade TCA function.
  • "Reliable pre-trade data for fixed-income is scarce, which makes price discovery and proving best execution a challenge," explained Jan-Theo Varkevisser, Global Head of Fixed Income Trading, PGGM.
  • "While trade cost models have become the norm in equities, developing a native model in fixed income markets is an exciting step forward to providing bond traders and portfolio managers with greater pre-trade intelligence."

Cerebain Biotech Closes Share Exchange Agreement With PKG, Inc.

Retrieved on: 
Monday, September 20, 2021
Medical Devices, Health, News, OTC, Risk, Engineering, Ownership, Omentum, PKG, CBBT, Twitter, Company, OTC Markets Group, Forward-looking statement, Dementia, Government, ID, Medical device

Cerebain Biotech Corp. (OTC: CBBT), (the Company or Cerebain) today announced that it has closed the Share Exchange Agreement with PKG, Inc. (PKG) thereby having total control and ownership of PKG, Inc.

Key Points: 
  • Cerebain Biotech Corp. (OTC: CBBT), (the Company or Cerebain) today announced that it has closed the Share Exchange Agreement with PKG, Inc. (PKG) thereby having total control and ownership of PKG, Inc.
    Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution.
  • The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimers disease.
  • Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.
  • PKG, Inc. was established in 1989 and is a privately held corporation based in Meridian, ID.